Avantor (NYSE:AVTR – Get Free Report) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.800-0.830 for the period, compared to the consensus estimate of 0.790. The company issued revenue guidance of -.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on AVTR shares. Wall Street Zen upgraded shares of Avantor from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Wolfe Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a research report on Thursday. Citigroup boosted their target price on shares of Avantor from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. UBS Group set a $8.00 target price on shares of Avantor in a research report on Wednesday, June 24th. Finally, Sanford C. Bernstein initiated coverage on shares of Avantor in a research note on Friday, June 26th. They set a “market perform” rating and a $10.50 price target for the company. Two research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Avantor currently has a consensus rating of “Hold” and an average price target of $12.00.
View Our Latest Analysis on Avantor
Avantor Trading Down 3.9%
Avantor (NYSE:AVTR – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.02. The company had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, research analysts forecast that Avantor will post 0.8 EPS for the current year.
Insider Buying and Selling
In other news, Director Gregory T. Lucier purchased 10,000 shares of Avantor stock in a transaction dated Friday, May 8th. The stock was purchased at an average cost of $8.32 per share, for a total transaction of $83,200.00. Following the transaction, the director directly owned 60,000 shares of the company’s stock, valued at approximately $499,200. This trade represents a 20.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.28% of the stock is currently owned by insiders.
More Avantor News
Here are the key news stories impacting Avantor this week:
- Positive Sentiment: Q2 earnings and revenue exceeded expectations. Avantor reported adjusted earnings of $0.21 per share versus the $0.19 analyst consensus, while revenue reached $1.69 billion, ahead of the $1.61 billion estimate. Although EPS declined from $0.24 a year earlier, revenue increased modestly year over year. Avantor Beats Q2 Earnings and Revenue Estimates
- Positive Sentiment: Management raised its 2026 outlook. Avantor now expects adjusted EPS of $0.80–$0.83 and is targeting adjusted net leverage below 3x. The improved guidance reflects VWR returning to organic growth earlier than expected and continued execution across business segments. Avantor 2026 Guidance
- Positive Sentiment: Analyst price targets moved higher. Wells Fargo raised its target from $14 to $16 and maintained an overweight rating. Stifel lifted its target from $8 to $15, while Morgan Stanley raised its target from $10 to $14. These revisions indicate improving confidence in Avantor’s earnings recovery and balance-sheet progress.
- Positive Sentiment: Additional analyst upgrades improved sentiment. Wolfe Research upgraded Avantor from “strong sell” to “hold,” following Jefferies’ move from “underperform” to “hold” on July 29.
- Neutral Sentiment: Analyst views remain mixed. The upgrades largely stop at “hold” or “equal weight,” suggesting that much of the earnings improvement may already be reflected in the stock’s valuation. Jefferies’ $13 price target is below the current market level, and Morgan Stanley’s $14 target implies limited upside.
- Negative Sentiment: Year-over-year profitability remains under pressure. Second-quarter EPS fell from the prior-year period, and Avantor continues to report a negative net margin, highlighting execution and profitability risks despite the stronger outlook.
Institutional Trading of Avantor
Several institutional investors and hedge funds have recently modified their holdings of AVTR. Wellington Management Group LLP purchased a new position in shares of Avantor during the fourth quarter worth about $268,584,000. Morgan Stanley raised its stake in Avantor by 179.4% in the fourth quarter. Morgan Stanley now owns 17,468,418 shares of the company’s stock valued at $200,188,000 after purchasing an additional 11,216,565 shares in the last quarter. Invesco Ltd. lifted its position in Avantor by 7.0% during the fourth quarter. Invesco Ltd. now owns 17,178,716 shares of the company’s stock valued at $196,868,000 after purchasing an additional 1,125,348 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Avantor by 9.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 14,606,596 shares of the company’s stock valued at $167,392,000 after purchasing an additional 1,222,850 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Avantor by 122.0% in the 2nd quarter. Bank of America Corp DE now owns 7,495,095 shares of the company’s stock worth $100,884,000 after buying an additional 4,119,522 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.
About Avantor
Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor’s offerings are organized across two primary segments.
Featured Stories
- Five stocks we like better than Avantor
- L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
